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Hindbrain administration of estradiol inhibits feeding and
activates estrogen receptor-alpha-expressing cells in the nucleus
tractus solitarius of ovariectomized rats
Abstract
17beta-estradiol (E2), acting via estrogen receptor (ER)-alpha, inhibits feeding in animals. One
mechanism apparently involves an increase in the satiating potency of cholecystokinin (CCK) released
from the small intestine by ingested food. For example, the satiating potency of intraduodenal lipid
infusions is increased by E2 in ovariectomized rats; this increased satiation is dependent on CCK, and it
is accompanied by increases in the numbers of ERalpha-positive cells that express c-Fos in a subregion
of the caudal nucleus tractus solitarius (cNTS) that receives abdominal vagal afferent projections. To
test whether direct administration of E2 to this area of the hindbrain is sufficient to inhibit food intake,
we first implanted 0.2 microg estradiol benzoate (EB) in cholesterol or cholesterol alone either sc or
onto the surface of the hindbrain over the cNTS. Food intake was significantly reduced after hindbrain
EB implants but not after sc EB implants. Next we verified that equimolar hindbrain implants of E2 and
EB had similar feeding-inhibitory effects and determined that only small amounts of E2 reached brain
areas outside the dorsal caudal hindbrain after hindbrain implants of (3)H-labeled E2. Neither plasma
estradiol concentration nor plasma inflammatory cytokine concentration was increased by either
hindbrain or sc EB implants. Finally, hindbrain EB implants, but not sc implants, increased c-Fos in
ERalpha-positive cells in the cNTS after ip injection of 4 microg/kg CCK-8. We conclude that E2,
acting via ERalpha in cNTS neurons, including neurons stimulated by ip CCK, is sufficient to inhibit
feeding.
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17β-estradiol (E2), acting via estrogen receptor-α (ERα), inhibits feeding in animals.  
One mechanism apparently involves an increase in the satiating potency of cholecystokinin 
(CCK) released from the small intestine by ingested food.  For example, the satiating potency 
of intraduodenal lipid infusions is increased by E2 in ovariectomized (OVX) rats, this 
increased satiation is dependent on CCK, and it is accompanied by increases in the numbers 
of ERα-positive cells that express c-Fos in a subregion of the caudal nucleus tractus solitarius 
(cNTS) that receives abdominal vagal afferent projections. To test whether direct 
administration of E2 to this area of the hindbrain is sufficient to inhibit food intake, we first 
implanted 0.2 µg estradiol benzoate (EB) in cholesterol or cholesterol alone either sc or onto 
the surface of the hindbrain over the cNTS.  Food intake was significantly reduced after 
hindbrain EB implants, but not after sc EB implants. Next we verified that equimolar 
hindbrain implants of E2 had similar feeding-inhibitory effects and determined that only small 
amounts of E2 reached brain areas outside the dorsal caudal hindbrain after hindbrain 
implants of 3H-labelled E2. Neither plasma estradiol concentration nor plasma inflammatory 
cytokine concentration was increased by either hindbrain or subcutaneous EB implants.  
Finally, hindbrain EB implants, but not sc implants, increased c-Fos in ERα-positive cells in 
the cNTS following ip injection of 4 µg/kg CCK.  We conclude that E2 acting via ERα in 
cNTS neurons, including neurons stimulated by ip CCK, is sufficient to inhibit feeding. 
 
KEY WORDS: food intake, satiation, sex differences, ERα 
 
ABBREVIATIONS: 
 
Arc, arcuate hypothalamic nucleus; AP, area postrema; cc, central canal; CCK, 
cholecystokinin; CeA, central nucleus of the amygdala; cNTS, caudal nucleus tractus solitarius; 
CPM, counts per minute; DAB, diaminobenzidine; E2, 17-β estradiol; EB, β-estradiol 3-
benzoate; ERα, estrogen receptor-α; IFN-γ, interferon-γ; Gr, gracilis nucleus; H-E2, hindbrain 
E2 implant; H-EB, hindbrain EB implant; MeA, medial nucleus of the amygdala; MPA, medial 
preoptic area; Ni, Nickel; NTS, nucleus tractus solitarius; Ob, obex; OC, occipital crest; OVX, 
ovariectomy; PB, phosphate buffer; pro-opiomelanocortin (POMC); PVN, paraventricular 
hypothalamic nucleus; RPa, raphe pallidus nucleus; sc-EB, sc EB implant; SED, standard error 
of the difference; spNTS, subpostremal nucleus tractus solitarius; VMH, ventromedial 
hypothalamic nucleus. 
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INTRODUCTION 
One of the many biological actions of 
17β-estradiol (E2) is its modulatory effect on 
eating.  In both rats and women, daily food 
intake decreases during the peri-ovulatory 
phase of the ovarian cycle (i.e., estrus in rats) 
(reviewed in: 1,2,3).  In addition, in rats, 
disruption of ovarian cycling by ovariectomy 
(OVX) chronically increases meal size and 
food intake, leading to increased adiposity 
(1,2,3).  E2 is sufficient to account for these 
effects in rats because a near-physiological, 
cyclic E2 treatment regimen maintained 
normal patterns of food intake and body 
weight after OVX (4,5).  E2 appears to inhibit 
feeding via estrogen receptor-α (ERα) because 
OVX ERα-knockout mice did not eat less 
following E2 administration (6). 
 
E2 inhibits feeding at least in part by 
increasing the potency of negative-feedback 
signals that control meal size, or satiation 
signals (1,2,3).  One such satiation signal is 
cholecystokinin (CCK), which is released from 
the proximal intestine during meals and 
produces a vagal satiation signal that is 
initially processed in the nucleus tractus 
solitarius (NTS) in the dorsal hindbrain (1,2,7, 
8,9,10).  Evidence that E2 increases CCK 
satiation comes from demonstrations that, in 
OVX rats, (i) E2 increases the satiating effect 
of exogenous CCK, (ii) increases the feeding-
stimulatory effect of CCK-1 receptor 
antagonism, and (iii) increases the satiating 
potency of intraduodenal lipid infusions (1,2,5, 
11).  
 
E2 appears to act in the brain to 
control feeding (1,2,3).  The specific brain 
site(s) where E2 acts to inhibit eating, 
however, remains unclear.  Direct 
administration of E2 into several hypothalamic 
areas, including the ventromedial 
hypothalamic nucleus (VMH) (12), the 
paraventricular nuclei (PVN; 13,14), the 
medial preoptic area (MPA; 15) have been 
reported to reduce food intake, and 
administration of E2 into the arcuate nucleus 
(Arc) has been reported to increase the 
feeding-inhibitory effect of exogenous leptin 
(16).  Whether any of these sites is involved in 
the physiological action of E2 on feeding 
remains controversial (1,2,3,16,17). 
 
E2-mediated changes in feeding-
related neuronal activation, measured by c-Fos 
immunocytochemistry, have been used to 
identify potential sites of the E2’s action on 
feeding.  In OVX rats, E2 treatment increases 
both feeding- and CCK-induced c-Fos 
expression in the NTS, the PVN, and the 
central nucleus of the amygdala (CeA) (18,19).  
E2 treatment also increased the satiating 
potency of intraduodenal infusions of lipid in 
OVX rats, an effect mediated by endogenous 
CCK, and this increased satiation was 
associated with increased c-Fos expression in a 
circumscribed population of neurons in the 
caudal NTS (cNTS) that express ERα (11).  
Therefore, here we sought to determine 
whether ERα-positive cNTS neurons are 
sufficient to mediate the estrogenic inhibition 
of feeding.  We report data supporting this 
hypothesis.  Open surgical administration of 
0.2 µg β-estradiol-3-benzoate (EB) onto the 
surface of the hindbrain over the cNTS, but not 
sc administration of the same EB dose, 
decreased food intake. Furthermore, the same 
EB treatment increased CCK-induced c-Fos 
expression in cNTS ERα cells, implicating 
CCK in the mechanism. 
 
MATERIALS AND METHODS 
Subjects 
Female Long-Evans rats (Centre d’Elevage R. 
Janvier, Le Genest-Saint-Isle, France) 
weighing 229 ± 2 g (mean ± SEM) were 
housed individually in hanging cages with 
stainless steel wire-mesh floors (33 x 18 x 20 
cm) in a room maintained at 22 ± 2 °C with a 
12:12-h light-dark cycle (lights on 0400 h).  
All rats had ad libitum access to pelleted 
standard laboratory chow (Provimi Kliba, 
Gossau, Switzerland) and tap water.  Prior to 
OVX, rats were adapted to the housing 
conditions for 3 wk and handled 3 d/wk prior 
to surgery.  All procedures were approved by 
the Canton of Zürich Veterinary Office. 
 
OVX and E2 Treatment 
Rats were anesthetized with isofluorane (2.5-
3% Attane, Minrad, Buffalo, NY, USA) and 
bilaterally ovariectomized using an intra-
abdominal approach.  Immediately after 
surgery, rats were sc injected with 
chloramphenicol (50 mg/kg; Septicol, 
Vetoquinol, Bern, Switzerland) for antibiotic 
prophylaxis and buprenorphine (1 mg/kg; 
Temgesic, Essex Chemie, Luzern, 
Switzerland) for analgesia. 
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E2 implants were prepared by pipetting 0.5 µl 
absolute ethanol (Fluka, Buchs, Switzerland) 
containing 9 µg/µl cholesterol (Sigma, St. 
Louis, MO, USA) and 0, 0.4 or 4 µg/µl EB 
(Sigma) onto ∼ 1 mm2 pieces of absorbable 
hemostat fabric (Collastas Aristavet, 
Ravensburg, FRG), which were then air-dried 
to yield implants containing 0, 0.2 or 2 µg EB, 
respectively. 
 
Two weeks after OVX, rats were anaesthetized 
with ip injections (1 ml/kg) of a mixture of 6 
mg/kg xylazine (Rompun, Provet, Lyssach, 
Switzerland) and 60 mg/kg ketamine 
(Narketan, Vetoquinol) and placed in a 
stereotaxic instrument with the neck 
ventroflexed.  A 15 mm midline skin incision 
was made above the occipito-atlantal joint, the 
neck muscles were retracted by blunt 
dissection, and the joint capsule was opened.  
A 2 mm incision was made in the dura, taking 
care not to damage the dorsal surface of the 
hindbrain, and an implant containing 0 or 0.2 
µg EB was placed on the hindbrain, centered  
just caudal to the area postrema (AP; i.e., about 
14. 1 mm caudal to bregma [20]). A 
photograph of the surgical site is shown in 
Figure 1A. The neck muscles were 
repositioned, and a second implant containing 
0, 0.2, or 2 µg EB was placed sc, just lateral to 
the skin incision, which was then sutured (the 
particular combinations used are described 
below).  Brains from rats sacrificed 1-7 d after 
implantation showed no evidence of gross 
pathology or alterations in cellular architecture 
as gauged by Nissl staining (Figure 1 B-C). 
The dose of 0.2 µg EB was chosen based on 
pilot studies indicating that central implants of 
this dose did not produce cornification of 
vaginal mucosal cells or increased uterus 
weight, two peripheral estrogenic effects.  The 
dose of 2 µg EB sc was chosen because this 
dose injected once every 4 d produces near-
physiological cyclic patterns of plasma E2 
concentration and normalizes food intake and 
body weight in OVX rats (5). 
 
Food intake and body weight. 
In order to determine if local administration of 
E2 to the hindbrain is sufficient to inhibit 
feeding, we compared the effects of implants 
of cholesterol alone (control implants; n = 9), 
0.2 µg EB on the hindbrain (n = 9) and 0.2 µg 
EB sc (n = 10) on daily food intake.  Food 
intake (± 0.1 g, corrected for spillage) and 
body weight (± 1 g) were measured at 1000 h 
for 3 d before and 6 d after implantation.  Data 
were analyzed with ANOVA (SAS GLM 
procedure; SAS Institute, Cary, NC, US) 
followed by Tukey’s honestly significant 
difference contrasts between individual means, 
and are reported as means ± SEM, with the 
standard error of the difference (SED) given to 
indicate experiment-wide residual variability.  
Tests were two-tailed, and minimum 
significance level was P < 0.05. 
 
Implantation surgery alone had marked effects 
on food intake and body weight.  One-way 
ANOVA of the means of the 3-d pre-operative 
period (which did not vary significantly, (F2,88 
= 1.19 and 0.85, Ps > 0.05, for food intake and 
body weight, respectively) and the 6-d post-
implant period showed that daily food intake 
did not recover fully until day 6, F6,53 = 85.03, 
P < 0.0001, SED = 0.5 g (Figure 2A).  Body 
weight also decreased transiently after surgery 
and recovered to the baseline level by day 5, 
F6,54 = 28.05, P < 0.0001, SED = 1 g (data not 
shown).  Therefore, the effects of EB implants 
were analyzed in the context of the surgery 
effects by separate one-way ANOVA done on 
each of the six treatment days. 
 
Spread of implanted E2. 
The spread of E2 through the brain after 
hindbrain implantation was assessed.  Ten rats 
received hindbrain implants of 0.2 µg E2 
mixed with 6 ng of 3H-labelled E2 (0.33 
µCi/ng; New England Nuclear, Perkin Elmer; 
Waltham MA, USA). Six, 12, 24 or 48 h later, 
one or two rats were deeply anesthetized with 
ip injections of sodium pentobarbital 
(Nembutal, 50 mg/kg, Abbott, Chicago, IL, 
USA). The implants were removed, and the 
fresh brains were removed and snap frozen. 
Coronal cryosections (100 µm sections 
through 3 mm of hindbrain centered on the 
implant site and seven 500 µm sections 
through the hypothalamus) were cut on a 
cryostat (Leica CM3050S; Nussloch, FRG). 
Three other rats were killed 12 h after 
implantation. Their hindbrains were cut into 
fifteen 200 µm sections, which were then cut 
horizontally just ventral to the level of the 
central canal, and the dorsal and ventral parts 
were counted separately. Brain sections were 
dissolved in 6 M KOH and then neutralized 
with ~6 M HCl. After addition of 5 ml 
scintillation fluid (Quicksafe A,  Zinsser 
Analytic, Berkshire, UK), radioactivity was 
counted in a beta-counter (Packard 1600 TR, 
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Canberra Packard, Zurich, Switzerland). 
Counts were corrected by subtracting the 
activity of corresponding brain samples from a 
rat not treated with 3H-labelled E2. Data are 
expressed as percent recovery of implanted 3H-
labelled E2, using the counts of freshly 
prepared 3H-labelled E2 pads as a reference, 
and as estimated counts per minute (CPM) per 
mm3 tissue. Tissue volumes were estimated as 
the product of section thickness and the area of 
the corresponding sections in the atlas of 
Paxinos and Watson (20). 
 
The kinetics of appearance of E2 in the brain 
after peripheral or central administration of EB 
have not been characterized. In one behavioral 
study, central implants of equimolar doses of 
EB and E2 had indistinguishable effects in ring 
doves (21). To insure that EB and E2 have 
similar behavioral effects under our conditions, 
we compared the effects of hindbrain implants 
of cholesterol alone (control implants; n = 8), 
0.2 µg EB (5.5 nMol; n=8), or 0.14 µg E2 (5.5 
nMol; n=8) on food intake and body weight, as 
above. 
 
Plasma E2 concentration. 
To determine whether hindbrain implants of 
0.2 µg EB increased peripheral plasma E2 
concentration, control implants (n = 16), 
hindbrain implants of 0.2 µg EB (n = 16), sc 
implants of 0.2 µg EB (n = 14), and sc 
implants of 2 µg EB (n = 17) were done.  Rats 
were anesthetized with isofluorane 10 h after 
implantation, and 1.5 ml blood was collected 
from the retro-orbital sinus.  This time point 
was chosen because previously, plasma E2 
levels were maximal 6-18 h after sc injection 
of 2 µg EB (5).  Plasma E2 concentration was 
measured using a double-antibody RIA 
(Diagnostic Products, Los Angeles, CA).  Two 
sets of standards were used, EB and E2, both 
diluted in serum from OVX rats.  For both 
standards, 1-min counts between 18 and 3336 
pmol/L were linear on a logit-log plot (r2 = 
0.998) and the intra-assay variability was 
3.2%.  Standards below 18 pmol/L were 
indistinguishable and were considered non-
detectable.  Because rat plasma contains high 
levels of nonspecific steroidal esterases, which 
convert EB to E2 (22), we assume that our 
assay results represent predominantly E2.  
Because the data were not normally distributed 
(Kolmogorov-Smirnov test, P < 0.001), they 
were analyzed using Kruskall-Wallis one-way 
ANOVA on ranks followed by Dunn’s test for 
pairwise comparisons and are reported as 
medians and interquartile ranges. 
 
Plasma pro-inflammatory cytokine 
concentrations. 
E2 can increase the severity of anorexia 
produced by administration of bacterial 
pathogens or cytokines (23,24).  Therefore, we 
measured the effects of hindbrain implants EB 
on plasma pro-inflammatory cytokine 
concentrations to investigate whether the 
feeding-inhibitory effect of this procedure 
might be due to an increased anorectic 
response to pro-inflammatory cytokines 
released after open-brain surgery.  Samples of 
1.5 ml blood were collected from the retro-
orbital sinus of rats receiving control implants 
(n = 6) or hindbrain implants of 0.2 µg EB rats 
(n = 6) 7 d prior to OVX, 7 d post-OVX, 
during implantation surgery, 10 h after 
implants, and 2 d after implants.  Plasma levels 
of interferon-γ (IFN-γ), TNF-α, IL-1β and IL-6 
were measured using a multiplex ELISA assay 
according to the manufacturer’s instructions 
(Bio-Plex Cytokine Assay system, BioRad 
Laboratories, Ismaning, FRG).  The detection 
limit was 50 pg/ml for each cytokine.  These 
data were not normally distributed because 
many individual values in each assay were 
below the detection limit (Kolmogorov-
Smirnov test, P < 0.001), so were analyzed 
using Kruskall-Wallis one-way ANOVA on 
ranks. 
 
CCK-induced c-Fos expression. 
CCK-induced c-Fos expression was measured 
in rats after control implants (n = 10), 
hindbrain implants of 0.2 µg EB (n = 10), or sc 
implants of 2 µg EB (n = 10).  Rats had been 
used previously for the plasma E2 assay.  
Three d after implant surgery, when the 
feeding-inhibitory effect of hindbrain E2 was 
largest (see Results), half of each group 
received ip injections of saline (1 ml/kg; 0.9 % 
NaCl, ip) and half ip injections of 4 µg/kg 
sulfated CCK-8 (Bachem, Bubendorf, 
Switzerland) at dark onset.  Ninety min later, 
the rats were deeply anesthetized with ip 
injections of sodium pentobarbital as 
previously and transcardially perfused with 
ice-cold phosphate buffer (PB, 0.1 M, pH 7.4) 
followed by 4 % paraformaldehyde in 0.1 M 
PB.  The brains were removed, postfixed at 4 
°C in the paraformaldehyde perfusion solution 
for 2 h and in 20% sucrose in 0.1 M PB for 2 
d, and then cut into 40 µm sections on a 
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freezing sliding microtome.  Sets of each sixth 
hindbrain (∼17 to 11 mm posterior to bregma; 
[20]) and forebrain (∼0.9 to 3.6 mm posterior 
to bregma,[20]) sections were stored in 
cryoprotectant solution (a 4:3:3 mixture of 0.1 
M PB, ethylene glycol, and glycerol; Sigma) at 
–20 °C. 
 
One set each of hindbrain and forebrain 
sections were processed for c-Fos expression 
using Nickel (Ni)- diaminobenzidine (DAB) 
immunocytochemistry.  Following a brief 
incubation in 0.5 % H2O2 in 0.1 M PB, 
sections were incubated for 1 h in 1 % normal 
goat serum (Vector Laboratories, Burlingame, 
CA, USA) solution in 0.1 M PB + 0.3 % 
Triton-X (Sigma) and then overnight, at room 
temperature, in primary antibody solution 
(1:20,000 rabbit polyclonal c-Fos antibody Ab-
5, EMD Biosciences, Darmstadt, FRG, in 0.3 
% Triton-X).  Next, sections were incubated 
for 1 h with biotinylated anti-rabbit goat IgG 
(1:300, Vector Laboratories), stained using the 
streptavidin-Ni-DAB-peroxidase complex 
reaction (ABC, 1:500, Vector), mounted on 
gelatin-coated microscope slides, dehydrated 
in an increasing series of alcohols, defatted in 
xylene, cover slipped with Permount (Biomeda 
Corp, Foster City, CA. USA), and air dried.  
Finally, the sections were digitally imaged 
(AxioCam, Carl Zeiss, Jena, FRG), and c-Fos 
positive cells were counted within the 
following areas of interest using templates 
based on the atlas of Paxinos and Watson (20); 
(NTS subregion nomenclature is our own; 
locations are mm caudal to bregma):  cNTS 
(about 14.4 - 14.1 mm); subpostremal NTS 
(spNTS; about 14.0 - 13.7 mm); PVN (1.8 - 
2.1 mm), Arc (2.8 - 3.1 mm), CeA (2.3 -2.8 
mm), raphe pallidus nucleus (RPa; 13.7 – 14.0 
mm), and VMH (2.3 -2.8 mm).  Cells were 
considered c-Fos positive if their nuclei 
contained punctate blue-black immunolabeling 
and were counted using constant minimum and 
maximum optical density and object size 
criteria, which were validated with visual 
counts.  Data for each area were analyzed with 
two-way ANOVA, with E2 treatment and 
CCK treatment each between-subjects factors. 
 
Co-localization of c-Fos and ERα. 
Double-label (ERα and c-Fos) 
immunoflourescence staining was used to 
determine whether EB hindbrain implants 
increased CCK-induced c-Fos expression in 
NTS cells expressing ERα.  spNTS and cNTS 
sections from saline- and CCK-injected rats 
that had received hindbrain implants of 0.2 µg 
EB (n = 7 each) from the previous experiment 
were processed using an immunofluorescence 
procedure for separate detection of two 
primary antibodies raised in rabbits (25, 26). 
Free-floating brain sections were incubated for 
10 min each in 1% sodium borohydride and 
0.5% H2O2 solutions, then for 1 h in 1% 
normal goat serum in 0.1 M PB + 0.3 % 
Triton-X, and overnight with rabbit polyclonal 
ER-α antibody (c1355, 1:100,000, Upstate 
Biotechnology, Lake Placid, NY, USA).  
Sections were then incubated with biotinylated 
anti-rabbit goat antibody and avidin-biotin 
complex, for 1 h each, as described above.  
The avidin-biotin signal was amplified for 30 
min with biotinylated tyramide solution (60 
µl/10 ml PBS + 1:1000 H2O2), and ERα was 
visualized with Cy2-conjugated Streptavidin 
(1:400, Jackson ImmunoResearch Lab, West 
Grove, PA, USA; peak emission 510 nm).  
Sections were washed and incubated for 1 h in 
1% normal donkey serum in 0.1 M PB + 0.3 % 
Triton-X, and overnight with c-Fos primary 
antibody (1:10,000, rabbit polyclonal c-Fos 
antibody Ab-5, EMD Biosciences) in 0.1 M 
PB, 0.3 % Triton-X and 1% normal donkey 
serum (Jackson) and then with Cy3-conjugated 
AffiniPure Donkey Anti-Rabbit IgG (Jackson; 
peak emission 570 nm).  Finally, sections were 
mounted on gelatinized microscope slides, 
dehydrated in a series of alcohols, defatted in 
xylene, cover slipped, dried, and digitally 
imaged. The numbers of cNTS cells expressing 
either ERα or c-Fos immunoreactivity were 
first counted with selective filters for Cy2 and 
Cy3 (sets 15, BP 515-565 nm, and 10, LP 570 
nm, respectively, Carl Zeiss, Feldbach, 
Switzerland).  The images were then 
overlayed, and cells expressing both labels 
were counted.  Several controls for label 
specificity were performed. In some sections 
the c-Fos primary antibody was omitted from 
the run. When this was done the Cy2 signal 
remained strong, but there was no Cy3 signal 
(data not shown). Furthermore, the Cy2 and 
Cy3 filters clearly revealed separate cells, both 
within individual brain areas (such as the 
cNTS, below) and between adjacent brain 
areas in which either ERα but not c-Fos or c-
Fos but not ERα was expressed (for example, 
in the CeA and Medial nucleus of the 
amygdala (MeA; data not shown). Finally, 
examination of some samples with 1-µm 
confocal imaging indicated that counts done 
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with light microscopic examination of the 40 
µm sections revealed true cellular co-
localization, not overlays of different cells (see 
below).  Counts from saline- and CCK-treated 
rats for each label and each area were analyzed 
with unpaired t-tests.  Because the co-
localization counts were not normally 
distributed (Kolmogorov-Smirnov test, P < 
0.01), they were analyzed using Mann-
Whitney Rank Sum tests and are reported as 
medians and interquartile ranges. 
 
RESULTS 
Food intake and body weight. 
Administration of 0.2 µg EB onto the surface 
of the hindbrain over the cNTS, but not sc 
administration of 0.2 µg EB, decreased food 
intake (Figure 2).  Neither treatment produced 
detectable effects on days 1 and 2 after 
implantation (F2,27 = 1.50 and 0.91, P > 0.05, 
SED = 0.7 and 0.6 g, for days 1 and 2, 
respectively).  On days 3 and 4 after 
implantation, however, food intake was 
significantly less in rats with hindbrain 
implants of 0.2 µg than in rats with either sc 
implants of 0.2 µg EB or control implants (F2,26 
= 11.13 and 4.28, P < 0.0003 and 0.03, SED = 
0.5 and 0.5 g, for days 3 and 4, respectively).  
Food intake returned to the control level on 
day 5 (F2,26 = 0.03 and 1.08, P > 0.05, SED = 
0.7 and 0.6 g, for days 5 and 6, respectively).  
There were no differences in body weight 
among the groups on any of the 6 post-implant 
days (data not shown). 
 
In the second experiment, administration of 
equimolar doses of EB and E2 (i.e., 0.2 µg EB 
and 0.14 µg E2, both 5.5 nMol) onto the 
surface of the hindbrain decreased food intake 
similarly (Table 1). As previously, neither 
treatment produced detectable effects on days 
1 and 2 after implantation (F2,21 = 2.86 and 
0.04, P > 0.05, SED = 0.7 and 0.6 g, for days 1 
and 2, respectively), but on day 3 after 
implantation food intake was significantly less 
both in rats with EB and E2 implants, and 
there was no detectable difference between the 
effects of EB and E2 (F2,21 = 6.09, P < 0.01, 
SED = 0.6 g). Unlike the first experiment, no 
statistically reliable effects were detected on 
day 4 after implantation (F2,21 = 0.85, P > 0.05, 
SED = 1.0 g). As previously, there were no 
differences in body weight among the groups 
on any day (data not shown).  
 
Spread of implanted E2. 
By 6 h post-implant, < 1% of implanted 3H-E2 
remained in the implanted pads. At this time, 
~0.1% of implanted 3H-E2, corresponding to 
~200 pg total E2, was recovered from the 
hindbrain sections and ~0.0007% 3H-E2, 
corresponding to <2  pg total E2, from the 
hypothalamic sections. Recoveries were lower 
at later time points (data not shown). 3H-
activity was markedly increased in the dorsal 
fractions of the 200 µm hindbrain sections 
from under the site of the implant (i.e., ~13.5  -
15.0 mm caudal to bregma) and was near 
background levels more anteriorly or 
posteriorly (Figure 3). In the ventral fractions, 
3H-activity was near background in all 
sections, even directly under the implant. 
 
Plasma E2 concentrations. 
In rats with control implants, hindbrain 
implants of 0.2 µg EB, and sc implants of 0.2 
µg EB implants, plasma E2 levels were below 
the detection limit (18 pmol/L) in more than 
75% of samples (data not shown).  In contrast, 
in rats with sc implants of 2 µg EB, plasma E2 
concentration increased to the range of intact 
females during the proestrus phase (5,27) of 
the estrus cycle (median 105 pmol/L, 
interquartile range 65-278 pmol/L) and was 
significantly more than in any of the other 
groups (Dunn’s tests, all Ps < 0.05, after 
Kruskall-Wallis ANOVA on ranks, H3 = 42.5, 
P < 0.001). 
 
Plasma pro-inflammatory cytokine 
concentrations. 
Plasma concentrations of TNF-α, IL-1 and 
INF-γ were below the detection limit (50 
pg/ml) at each time point in both rats receiving 
hindbrain implants of 0.2 µg EB and rats 
receiving control implants.  Measurable 
concentrations of IL-6 were detected, but these 
were not different before vs. after implantation 
in either rats receiving hindbrain implants of 
0.2 µg EB or control rats (H4 = 4.45 and 4.00, 
P = 0.35 and 0.41, respectively). 
 
CCK-induced c-Fos expression. 
Hindbrain implants of 0.2 µg EB increased the 
expression of c-Fos in response to ip injection 
of 4 µg/kg CCK-8 in both cNTS and spNTS, as 
visualized by DAB staining (Figure 4).  In 
contrast, neither sc implants of 0.2 µg EB, nor 
control implants increased CCK-elicited c-Fos 
did in either area.  Post-hoc comparisons were 
based on ANOVA EB main effects and EB x 
CCK interaction effects (F1,22 = 7.53 and 8.10, 
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P < 0.05 and P < 0.01, and F2,22 = 5.08 and 
3.41, P <  0.02 and P = 0.051, SED = 1.2 and 
1.2 cells/section, for the cNTS and spNTS, 
respectively). 
 
No significant effects of either ip CCK or EB 
treatment on c-Fos expression were detected in 
any of the other brain areas tested (Figure 3; 
range of main effects of CCK and E2, F1,24 = 
0.11-2.22, Ps > 0.05; range of interaction 
effects, F2,24 = 0.71-2.15, Ps > 0.05). 
 
Co-localization of c-Fos and ER-α. 
As previously reported (11, 28-30), ERα was 
more abundantly expressed in the cNTS (~15 
cells/section) than in the spNTS (~5 
cells/section) (data not shown).  As in the 
DAB-stained sections, CCK injection 
significantly increased c-Fos expression 
visualized by fluorescence staining in both the 
cNTS (Figure 5A; t12 = 3.75, P < 0.01, SED = 
3.7 cells/section) and in the spNTS (9.5 ± 5.9 
and 51.8 ± 9.7 cells/section for saline and 
CCK-injected rats, respectively, t12 = 3.44, P < 
0.01, SED = 12.3 cells/section).  In the cNTS 
~25% of the c-Fos-positive cells in CCK-
injected rats also expressed ERα, whereas no 
c-Fos/ERα double-labeled cells were detected 
in the saline-injected rats (Figure 5A-B, Mann-
Whitney rank test, U = 3.50, P < 0.01).  In the 
spNTS, only one c-Fos/ERα double-labeled 
cell was detected in the 7 CCK-injected rats, 
and no double-labeled cells were detected in 
the saline-injected rats. 
 
DISCUSSION 
We demonstrate here that in OVX rats, 
open-surgical administration of 0.2 µg EB or 
an equimolar dose (5.5 nMol) of 0.14  µg E2 
directly onto the surface of the hindbrain just 
caudal to the AP, i.e., just over the cNTS, 
elicited a transient decrease in food intake, i.e., 
3-4 d later. The timing and duration of this 
decrease in feeding is similar to that elicited by 
sc administration of near-physiological doses 
of E2 (4,5).  Furthermore, hindbrain EB 
implants appeared to induce only local 
increases in E2 concentration. Finally, 
hindbrain EB implants also increased the 
neuronal activation of cNTS ERα-expressing 
neurons that was induced by ip CCK, a 
satiation signal which previously has been 
shown to mediate the feeding-inhibitory effect 
of E2 (1-6,11).   Our interpretation of these 
data is that E2 acts via ERα neurons in the 
cNTS to inhibit feeding by increasing satiation. 
 
Several previous reports have 
indicated that E2 acts in the brain, rather than 
peripherally, to inhibit eating, but have not 
clearly disclosed the site(s) of the ER involved 
(1,2,3).  The data reported here provide 
compelling evidence that one site where E2 
can act to inhibit feeding is the cNTS.  The 
strongest support for a local action in the cNTS 
comes from our measurements of the effects of 
cNTS implants on brain and systemic E2 
levels.  First, neither hindbrain nor sc 
administration of 0.2 µg EB led to a detectable 
increase in systemic plasma E2 concentration, 
indicating that each of these E2 treatments 
produced only local increases in E2. Second, 
hindbrain implants containing 3H-E2 increased 
brain E2 concentrations to biologically 
significant levels only in the dorsal hindbrain 
just under the implant site, i.e. in and around 
the cNTS. The increase in radioactivity 
corresponded to a total amount of at most ~200 
pg E2. The anterior-posterior spread of 3H-E2 
in this study is similar to that reported by 
Davis et al. (31, 32) to result from 
intrahypothalamic implants of about 3 ng E2 
(i.e., a 1:300 mixture of E2 in cholesterol in a 
28 ga implant needle). Implanted into the 
VMH, and together with peripheral 
progesterone treatment, this amount of E2 
increased sexual receptivity in OVX rats. In 
contrast, the smallest intrahypothalamic dose 
of E2 reported to inhibit feeding is about ~30 
times greater (i.e., the 1:10 E2:cholesterol 
mixtures used by Butera and his colleagues 
(13,14); discussed further below). Our 
hindbrain E2 implants increased E2 contents in 
more distal hindbrain sites by about an order of 
magnitude less than the increase in the 
immediate area of the cNTS and increased 
hypothalamic E2 contents about two orders of 
magnitude less. We regard these small 
increases as biologically insignificant. ERα in 
this part of the dorsal hindbrain are 
predominately localized in the cNTS (11, 28-
30), with sparse expression in the spinal 
trigeminal nucleus, an area not implicated in 
the control of feeding by gastrointestinal 
signals. Thus, we conclude that our hindbrain 
E2 implants acted in the cNTS to inhibit 
feeding.  
Two additional observations provide 
indirect support for this conclusion. First, the 
same dose of 0.2 µg EB used for  the hindbrain 
implants had no effect on food intake when 
implanted sc, adjacent to the hindbrain surgical 
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site, indicating that this dose of E2 is not 
sufficient to inhibit eating when administered 
outside the brain.  Second, pilot studies (data 
not shown) indicated that hindbrain 
administration of 0.2 µg EB did not produce 
the typical estrous pattern of cornified vaginal 
mucosal cells, a peripheral action, whereas 
doses of 0.5 µg EB or more did. 
 
Our c-Fos study was based on our 
report (11) that sc injections of 10 µg EB 
increased the satiating potency of 
intraduodenal infusions of fat emulsions in 
OVX rats, that this was mediated by 
endogenous CCK, that it was associated with 
increased c-Fos expression only in the cNTS, 
and that many of the cNTS cells that expressed 
c-Fos also expressed ER-α. The results here 
were similar.  Hindbrain EB treatment (i) 
decreased feeding, (ii) increased CCK-induced 
c-Fos expression only in the cNTS and spNTS 
(and not in forebrain areas related to the 
control of food intake, i.e., the PVN, VMN, 
and Arc), and (iii) increased c-Fos expression 
in ERα-positive neurons in the cNTS.  The 
highly restricted rostral-caudal extent of c-Fos 
activation in the NTS here is especially 
interesting because this region seems to 
receive vagal projections from the intestines 
(33).  Thus, it seems likely that intraduodenal 
lipid infusion in the previous experiment (11) 
led to activation of the same cNTS ERα-
expressing cells that CCK injection did here 
and, in turn, that in both tests, these cells were 
part of the neuronal network mediating the 
estrogenic inhibition of feeding.  Because 
hindbrain EB treatment was not sufficient to 
increase CCK-induced c-Fos in the 
hypothalamus, it is less likely that E2 acted 
there to inhibit eating. 
 
Our data do not address whether 
endogenous E2 also acts in brain sites outside 
the NTS to inhibit feeding.  Previous studies 
using intracranial administration of amounts of 
E2 that may have had only local effects (i.e., 
less than 0.5 µg) have implicated ER in three 
hypothalamic areas in the estrogenic inhibition 
of eating, but in each case the evidence is 
controversial (see (1,2,3) for reviews).  The 
most extensive data are those of Butera and his 
colleagues (13,14), who reported that 
implantation of E2 into the PVN significantly 
decreased food intake.  In their experiments, 
the distal 1 mm of a 28 ga cannula was filled 
with about 1 µg of cholesterol-E2 mixtures, so 
that the effective 3:1 and 10:1 cholesterol:E2 
mixtures translate into doses of about 0.3 and 
0.1 µg E2, respectively.  The evidence that 
these doses worked locally, within the PVN, 
was that even undiluted E2 (1 µg) delivered 
into the MPA, VMH or posterior 
hypothalamus failed to inhibit feeding and that, 
in comparison to undiluted E2, dilute E2 
implants in the PVN produced fewer 
occurrences of cornification of the vaginal 
mucosa and, in combination with progesterone, 
significantly less lordosis (13).  In addition, sc 
injections of E2 did not decrease feeding in 
rats with bilateral electrolytic lesions of the 
PVN (34).  These data suggested that E2 could 
act in the PVN to inhibit eating.  This 
conclusion remains controversial, however, 
because other laboratories have reported 
conflicting results.  Dagnault and Richard (35) 
failed to find any decrease in the feeding-
inhibitory potency of sc EB treatment in rats 
with similar electrolytic lesions of the PVN, 
and Hrupka et al. (17) failed to find any 
reliable eating-inhibitory effect of PVN EB 
implants similar to those that Butera et al. 
(13,14) reported to be effective. 
 
Dagnault and Richard (15) also 
investigated the role of the MPA in the 
feeding-inhibitory action of E2.  These 
investigators reported that food intake was 
reduced 2 h following injection of a water-
soluble, cyclodextrin E2 preparation into the 
MPA, but had recovered to control levels by 
13 h post-injection.  The time course of this 
inhibition does not match that produced by 
peripheral injections of E2, which typically 
decrease food intake with a latency of > 1 d, 
despite that plasma E2 levels reach maximal 
levels in only about 6 h (i.e., 4, 5).  Because 
cyclodextrin has been shown to interfere with 
neuronal function (36, 37), that Dagnault and 
Richard (15) used water rather than the 
cyclodextrin vehicle for control injections 
suggests that some or all of the effects that 
they reported may have been due to 
cyclodextrin rather than E2.  Consistent with 
this possibility, other investigators have failed 
to detect any inhibition of feeding after MPA 
implants of E2 (13, 17). 
 
Two more recent reports have 
implicated the Arc in the estrogenic inhibition 
of eating. Clegg et al. (16) provided evidence 
that E2 may act in the Arc to inhibit feeding by 
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increasing the potencies of the feeding-
inhibitory adiposity hormones leptin and 
insulin.  Despite affecting the potencies of 
exogenous insulin and leptin, however, Arc E2 
implants alone did not inhibit feeding.  It is 
possible that this was because the rats were 
tested several weeks after OVX, when the 
initial hyperphagia usually wanes, but this has 
not yet been verified. Gao et al. (38) reported 
that the feeding-inhibitory effects of 
intracerebroventricular E2 treatment are 
associated with increases in the number of 
excitatory pro-opiomelanocortin (POMC) 
synapses in the Arc. The physiological 
relevance of these data is questionable, 
however, because a central dose of 2 µg E2 
was used and because the inhibition of feeding 
occurred much more rapidly than after more 
physiological E2 treatments (1,2,5). In 
summary, although E2 may act in brain sites 
outside the NTS to inhibit feeding, at present 
there is no compelling evidence for this. 
 
In addition to eliminating the peri-
ovulatory decrease in eating, OVX also 
increases food intake to a level higher than that 
displayed at any phase of the normal estrus 
cycle.  This suggests that ovarian function, 
specifically E2 secretion, exerts both a tonic 
and a phasic, or cyclic, inhibition of feeding 
(1,2,5,39,40).  The tonic inhibitory effect on 
feeding is reflected in the higher level of food 
intake throughout the cycle in OVX rats 
compared to intact rats, and the phasic effect is 
reflected in the cyclic, peri-ovulatory decrease 
in food intake during the estrous cycle.  The 
evidence that CCK mediates the phasic 
inhibitory effect is that the CCK-1 receptor 
antagonist devazepide increased meal size only 
in estrus but not in diestrus, which suggests 
that endogenous CCK satiation, varies across 
the estrus cycle (41).  Our current 
demonstration that E2 acts in the hindbrain to 
transiently inhibit feeding and increase CCK-
induced c-Fos expression, taken together with 
the previous observation that CCK selectively 
mediates the phasic estrogenic inhibition of 
feeding, suggests that E2 acts in the hindbrain 
to mediate the phasic estrogenic inhibition of 
feeding.  It is important to note, however, that 
our data do not disclose whether or not E2 also 
acts on the hindbrain to mediate the tonic 
estrogenic inhibition of feeding. 
 
E2 can increase the severity of illness 
anorexia produced by peripheral 
administration of bacterial pathogens or pro-
inflammatory cytokines (23,24).  Because 
open-surgical implantation of E2 onto the 
surface of the hindbrain poses the risk of post-
surgical inflammation, we tested whether the 
inhibition of food intake that we observed 3-4 
days after E2 administration might be related 
to increases in plasma pro-inflammatory 
cytokines.  Plasma concentrations of the pro-
inflammatory cytokines IL-1, IFN-γ and TNF-
α were below the detection limit both before 
and after implant surgery, and although IL-6 
was detected in the plasma, its concentration 
did not increase after surgery.  The low level 
of c-Fos expression in the posterior RPa also 
suggests the absence of post-surgical 
inflammation, because c-Fos activation in this 
area has been linked to activation of the innate 
immune system by either peripheral or central 
inflammation (42-44).  Finally, there were no 
signs of pathology in post-mortem 
examinations of the brains. Thus, taken 
together, the data suggest that our rats did not 
suffer from systemic post-surgical 
inflammation.  Nonetheless, we cannot 
definitely rule out any influence of 
inflammation on food intake under our 
conditions because we did not identify the 
cause of the post-implantation reduction in 
food intake in the control group and we did not 
determine whether our surgical approach 
produced local inflammation within the brain. 
More generally, we emphasize that because all 
our data were collected during a period of 
postoperative recovery, their relevance to 
normal physiological function requires further 
substantiation. 
 
In conclusion, by demonstrating that 
hindbrain implants of 0.2 µg EB both inhibits 
feeding and activates ERα-containing neurons 
in the cNTS, the current experiments identify a 
new mechanism for the estrogenic control of 
feeding and provide a putative function for 
ERα in neurons in this region of the NTS.  
Furthermore, both these and previous data (11) 
suggest that one mechanism through which 
NTS ERα inhibits feeding is by increasing the 
neuronal processing of vagal afferent inputs 
encoding satiation signals initiated by 
intestinal CCK.  An important next step in 
understanding this process would be to identify 
the neurotransmitter phenotypes and inter-
neuronal connections of these neurons.  Some 
details about these NTS neuronal networks 
have begun to emerge recently.  In mice, ip 
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CCK increases c-Fos expression in NTS cells, 
including the spNTS and cNTS cells, that 
receive monosynaptic vagal inputs and in 
many cases also express POMC, the precursor 
of the neuropeptide α-MSH (45,46).  These 
cells appear to be a necessary part of CCK-
satiation information processing because 
fourth ventricular administration of an 
antagonist to the relevant α-MSH receptors, 
the melanocortin-3 and -4 receptors, 
completely blocked the satiating action of ip 
CCK-8 (45).  Appelyard et al. (44) also 
demonstrated that these POMC neurons were 
synaptically sensitive to opioids, glutamate, 
and CCK.  Similarly, Berthoud et al. (47) 
demonstrated that NTS cells, again including 
those in the spNTS and cNTS, which 
expressed c-Fos after intraduodenal infusions 
of linoleic acid or glucose in most cases also 
expressed both NMDA- and non-NMDA 
glutamate receptors.  Future elaboration of the 
roles of ERα in these hindbrain neuronal 
networks controlling appetite has clear 
translational importance for the understanding 
and development of sex-specific therapies for 
disordered eating, which disproportionately 
affects women (1,2,3). 
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FIGURE LEGENDS 
 
Figure 1. (A) Photograph of the surgical window for implant placement. Note that the AP lies 
just rostral to the obex (Ob) and is obscured by the occipital crest (OC) in this image. Dotted-
line square: approximate location of hindbrain implants; solid-line square, approximate 
location of sc implants (between muscle layers). Inset: the absorbable hemostatic cloth used for 
implants, cut to size and photographed at same magnification. (B) Photomicrograph of Nissl-
stained coronal section of the dorsal hindbrain at the level of the implant in an intact rat. (C) 
Photomicrograph of Nissl-stained coronal section of the dorsal hindbrain at the level of the 
implant, three days after implantation of 0.2 µg EB. Gr, gracilis nucleus. 
 
Figure 2. Open-surgical hindbrain implants of 0.2 µg EB (H-EB), but not sc implants (sc-
EB), decrease food intake in OVX rats.  Food intake was measured daily at the middle of the 
light phase (dotted lines).  Implants were done during the diurnal period of day 0 (arrow).  
Food intakes were not different among groups before implant surgery (days -2, -1 and 0) or 
after implantation on days 1 and 2, but food intake was decreased on post-implant days 3 and 
4 in H-EB rats.  (A) Mean ± SEM daily food intake in each group through the experiment. 
*Different from control and from sc-EB groups, P < 0.05.  (B) Food intake on days 3 and 4 
after implantation in H-EB and sc-EB rats expressed as differences from control group 
intakes.  The SED on both day 3 and 4 was 0.5 g. **(H-EB – control) different than (sc-EB - 
control), P < 0.01. 
 
Figure 3. Radioactivity measured in the dorsal (unshaded bars) and ventral (shaded bars) 
parts of 200 µm coronal sections of the hindbrain 12 h after hindbrain implants of  0.2 µg E2 
mixed with 6 ng of 3H-labelled E2 (0.33 µCi/ng). Data are mean ± SEM CPM/mm3 tissue 
(estimated from the cross sectional area of the sections in ref [20]) from 3 rats. Initial activity 
of the implants was ~3,700,000 CPM.  Black bar indicates approximate location of implant 
pads. 
 
Figure 4. Open-surgical hindbrain implants of 0.2 µg EB (H-EB), but not sc implants of 0.2 
µg EB (sc-EB), increase CCK-induced c-Fos expression, visualized with DAB staining, in the 
cNTS and spNTS, but not in the Rpa, PVN, VMN, or Arc.  Animals were killed on post-
implant day 3, 90 min after ip injection of 4 µg/kg CCK-8 or saline.  Data are number of c-
Fos positive cells/40 µm section, mean ± SEM.  *Number of c-Fos positive cells different in 
CCK-injected H-EB rats than in saline-injected H-EB rats, P < 0.05. + Increase in number of 
c-Fos positive cells in H-EB group (H-EB/CCK – H-EB/saline) different than in sc EB group 
(sc-EB/CCK – sc-EB/saline) or control group (control/CCK – control/saline), P < 0.05. 
 
Figure 5. CCK activates cNTS ERα-positive cells in rats that received open-surgical 
hindbrain implants of 0.2 µg EB (H-EB).  (A) Numbers of single-labelled ERα-positive cells 
(left columns), single-labelled c-Fos-positive cells (middle columns), and double-labelled 
ERα/c-Fos-positive cells (right columns). Note, all ERα/c-Fos values in saline-injected rats 
were 90 min after ip injection of saline or 4 µg/kg CCK-8 (CCK), visualized with 
immunoflourescence staining.  In left and middle columns, data are mean ± SEM numbers of 
ERα- or c-Fos- positive cells/section; in right columns, data are median number of ERα/c-Fos 
positive cells/section; individual c-Fos single-labeling and ERα/c-Fos double-labeling data 
are shown in the middle and right CCK columns, with lines connecting each rats data.  
*Number of c-Fos-positive cells different in saline- and CCK-injected rats, P < 0.05. + 
Number of ERα/c-Fos-positive cells different in saline- and CCK-injected rats, P < 0.05.  (B). 
Optical micrographs of a 40 µm cNTS section showing immunoflourescence staining of ERα 
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single labeling, c-Fos single labeling, and ERα/c-Fos double labeling (overlay) and a 1 µm 
confocal micrograph of ERα/c-Fos double labeling in area indicated by white box in overlay  
(confocal overlay).  Asterisks indicate representative double-labeled cells. Scale bars, 30 µm 
in optical micrographs and 10 µm in confocal micrograph.  
 






